OPT-Neuro: Longitudinal Observational Biomarker Study
Study Details
Study Description
Brief Summary
The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function. The study will also test if changes in brain structure and function are associated with decreases in memory. In this study, investigators will conduct a series of assessments/tests, mainly brain imaging and assessments of participant's memory and attention, to better understand how depression is linked to memory and thinking in older persons. Investigators hope that their study will help the scientific community to understand why some people with depressive symptoms that are resistant to treatment in late-life experience declines in their memory and attention and whether effective treatment of such depression reduces that risk. Finally, investigators hope that this study will eventually lead to the development of better treatment options.
Study Design
Outcome Measures
Primary Outcome Measures
- Persistent Depression Leading to Change in Cognition [Baseline, 6-months, 24-months]
To test whether persistent (non-remitting) depression has the ability to change cognition and lead to greater cognitive decline, and greater degradation of neural circuitry
Secondary Outcome Measures
- Change in Neural Circuity [Baseline, 6-months, 24-months]
To test whether greater degradation of neural circuitry is associated with greater cognitive decline
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Men and women aged 60 and older
-
Current Major Depressive Disorder (MDD)
-
Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length
-
Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher
Exclusion Criteria:
-
Dementia
-
Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms.
-
High risk for suicide and unable to be managed safely in the clinical trial
-
Non-correctable, clinically significant sensory impairment interfering with participation
-
Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management.
-
Moderate to severe substance or alcohol use disorder
-
Seizure disorder.
-
Parkinson's Disease
-
Individuals with any contraindications to MRI
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UCLA Late-Life Mood, Stress, and Wellness Research Program | Los Angeles | California | United States | 90095 |
| 2 | Washington University School of Medicine Healthy Mind Lab | Saint Louis | Missouri | United States | 63110 |
| 3 | Columbia University Adult and Late Life Depression Clinic | New York | New York | United States | 10032 |
| 4 | UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program | Pittsburgh | Pennsylvania | United States | 15213 |
| 5 | Centre for Addiction and Mental Health | Toronto | Ontario | Canada | M6J 1H1 |
Sponsors and Collaborators
- Centre for Addiction and Mental Health
- National Institute of Mental Health (NIMH)
- Patient-Centered Outcomes Research Institute
Investigators
- Principal Investigator: Aristotle Voineskos, MD, Centre for Addiction and Mental Health
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 080/2017
- R01MH114970
- R01MH114980
- R01MH114969
- R01MH114981
- R01MH114966-01